HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo
- 5 March 2008
- journal article
- review article
- Published by Elsevier in Virus Research
- Vol. 134 (1-2), 104-123
- https://doi.org/10.1016/j.virusres.2007.12.021
Abstract
No abstract availableKeywords
This publication has 168 references indexed in Scilit:
- Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptaseVirus Research, 2008
- HIV-1 Protease Dimer Interface Mutations that Compensate for Viral Reverse Transcriptase Instability in Infectious VirionsJournal of Molecular Biology, 2007
- A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1Science, 2007
- Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistanceProceedings of the National Academy of Sciences, 2007
- Risk of selecting resistance mutations during treatment interruptionCurrent Opinion in HIV and AIDS, 2007
- In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and LamivudineAntimicrobial Agents and Chemotherapy, 2006
- Antibody neutralization and escape by HIV-1Nature, 2003
- Novel Deletion of HIV Type 1 Reverse Transcriptase Residue 69 Conferring Selective High-Level Resistance to NevirapineAIDS Research and Human Retroviruses, 2001
- Primary and Recombinant HIV Type 1 Strains Resistant to Protease Inhibitors Are Pathogenic in Mature Human Lymphoid TissuesAIDS Research and Human Retroviruses, 2001
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996